LINCOLN PHARMA LTD
Latest filings
Next results: Thu, 29 Oct · Financial Results- Board meeting set for October quarter and half-year results · Results
- Sr GM Quality Assurance resigns from Lincoln Pharma · Management Changes
- Lincoln Pharma 32nd AGM: dividend and director reappointments approved · Board & Shareholder Meetings
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical formulations spanning cardiac, diabetic, dermatology and ENT therapy areas, selling both in India and overseas markets. Exports are diversified across African, Latin American, South-East Asian, institutional-tender and Canadian markets, with a Cepha manufacturing block now past breakeven and Canadian sales run through 6 Health Canada-approved product lines. R&D spend is being stepped up to support growing dossier filings, while the company is exploring entry into oncology and hormones alongside inorganic acquisitions in tablet and injectable manufacturing. Materials (35.7% of revenue) and employee costs (18.7%) are the largest cost lines, and management has guided to an INR1,000 crore revenue target with a stated 5-6 month slippage buffer on the original FY28 timeline.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Nothing flagged in the filed numbers.Charts
How has the market priced it — with filings on the timeline?
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from LINCOLN PHARMA LTD's filed financials and exchange disclosures
What does LINCOLN PHARMA LTD do?
LINCOLN PHARMA LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol LINCOLN.
Is LINCOLN PHARMA LTD profitable?
Yes. Over the trailing twelve months LINCOLN PHARMA LTD reported a net profit of ₹96 Cr on revenue of ₹694 Cr.
Does LINCOLN PHARMA LTD pay a dividend?
Yes. The dividend yield is 0.32% at the current price. It paid out 4% of its profit as dividend in FY26.
Is LINCOLN PHARMA LTD debt-free?
On a net basis, yes. It reported borrowings of ₹4.42 Cr on its 31 Mar 2026 balance sheet, but holds ₹17 Cr more cash than debt.
Is LINCOLN PHARMA LTD expensive compared with its peers?
On trailing P/E, LINCOLN PHARMA LTD ranks 28 of 158 in Pharmaceuticals — cheaper than 83% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the LINCOLN PHARMA LTD share price move in a day?
On a typical session LINCOLN PHARMA LTD moves 0.97% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are LINCOLN PHARMA LTD's next results?
Financial Results on Thu, 29 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track LINCOLN PHARMA LTD's announcements?
Every NSE and BSE filing by LINCOLN PHARMA LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.